Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease
about
sameAs
Aspirin in the Chemoprevention of Colorectal Neoplasia: An OverviewAbciximab does not inhibit the increase of thrombin generation produced in platelet-rich plasma in vitro by sodium arachidonate or tissue factorAspirin and clopidogrel resistance: an emerging clinical entityAspirin resistance and its implications in clinical practiceDose of aspirin in the treatment and prevention of cardiovascular disease: current and future directionsEfficacy and costs of secondary prevention with antiplatelets after ischaemic strokeOral antiplatelet therapy and percutaneous coronary interventionThe Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?Eptifibatide: The evidence for its role in the management of acute coronary syndromes.Risk of thrombocytopenia with glycoprotein IIb/IIIa inhibitors across drugs and patient populations: a meta-analysis of 29 large placebo-controlled randomized trials.The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus IntracoronaryOptimization of antiplatelet/antithrombotic therapy for secondary stroke prevention.Safety of low-dose aspirin in endovascular treatment for intracranial atherosclerotic stenosis.The exclusion of patients with chronic kidney disease from clinical trials in coronary artery diseaseAntiplatelet therapy in secondary stroke prevention--state of the artImpact of Dabigatran versus Phenprocoumon on ADP Induced Platelet Aggregation in Patients with Atrial Fibrillation with or without Concomitant Clopidogrel Therapy (the Dabi-ADP-1 and Dabi-ADP-2 Trials).Aspirin for the prevention of colorectal cancerBisphosphonates as anti-inflammatory agents in ankylosing spondylitis and spondylarthropathies.Tirofiban for the treatment of ischaemic stroke.A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass.Higher coated-platelet levels are associated with stroke recurrence following nonlacunar brain infarction.Pharmacological treatment and prevention of cerebral small vessel disease: a review of potential interventionsAvoiding and managing bleeding complications in patients with non-ST-segment elevation acute coronary syndromes.Medical prevention of stroke and stroke recurrence in patients with TIA and minor stroke.Antithrombotic medication for stroke prevention.Aspirin inhibit platelet-induced epithelial-to-mesenchymal transition of circulating tumor cells (Review).Antiplatelet therapy in acute coronary syndromes.The evolution of antiplatelet therapy in cardiovascular disease.Optimal aspirin dose in acute coronary syndromes: an emerging consensus.P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.Update of secondary stroke prevention.Comparison of clinical trial outcome patterns in patients following acute coronary syndromes and in patients with chronic stable atherosclerosis.Low-dose versus high-dose aspirin after percutaneous coronary intervention: analysis from the guthrie health off-label StenT (GHOST) registry.Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling?Bleeding risks of combination vs. single antiplatelet therapy: a meta-analysis of 18 randomized trials comprising 129,314 patients.Neuropsychological state of the population living in the Aral Sea region (zone of ecological crisis).Acute secondary stroke prevention trials in minor stroke/TIA: prime time for magnetic resonance imaging.
P2860
Q22306433-63587831-3F2F-4A12-B144-0F8003E35A5EQ28183647-8681A05E-BE26-4220-8E67-ED9D3A8C81C0Q28194021-9153D138-2E0B-4DCD-B8CC-1E0BE936EC06Q28194069-1EBD54E3-B48E-4992-9913-6137D110CA83Q28200895-AF9EC0FD-FDE1-4220-8164-83AE963B6592Q28211452-CAF22EC5-AE71-47D7-9EA2-71A5D4C3B685Q28217724-68C81CF8-5523-4A67-87FE-E876B9491D59Q33387192-2FF94760-163D-4141-8080-6FB4EAAE87A0Q33391279-1CF4D7BB-6C65-4A49-99F8-50C60E4396C9Q33434702-C3DB3779-5C7E-4DCB-A411-9761447CD7D0Q33572281-1A47601E-B0B3-4660-8BF4-F10664CDBB84Q33810226-B60BE179-2A06-4C40-BF04-A33F28AD1A87Q34075412-77843794-9AAF-4F0F-A27A-30C79F9FC614Q34175429-D8D5A2DF-5E13-4297-9C2F-BCA015259862Q35216412-FC522DF1-89A7-49AC-A006-38D1FEB0AD67Q35851558-E70F28E0-77FC-4721-8FBE-4039E98B3A46Q35967304-AB512952-73BA-4A80-A409-B25DF65C65C6Q36040667-7D8F561F-F257-476B-8B76-F27E0C325C4AQ36349613-66DF3817-C907-4E0B-92DC-151B6B258E4FQ36374457-CC0862FB-73C5-4941-B97C-7FB063BCEDC7Q36587083-0AF88B2C-412A-4A5D-891A-707EC9F99026Q36799847-5F0903D9-4B16-40B6-9E66-9AE7648B6629Q37175915-0B8791C7-01A3-4033-BF9E-6C7C6086BE96Q37532590-7D94075C-4F63-4270-9BF2-05FA86870563Q37611046-9842040C-3BD0-4191-A7FC-E055F3D8CF54Q37708482-142DA92E-0D78-4432-9202-8FC6D87DF620Q37798110-E474B394-56E9-47E1-B318-CE9BF0F0EB2FQ37900470-3F9ECBA6-5A42-49F7-9B1A-A58A90A378DCQ38206844-141AF804-8CBD-41CD-A506-3AC5CFCD9719Q38420789-7AA10C43-385A-4B94-AC41-5D261B5E3745Q43078028-7487CDB0-A74D-47BB-9403-4592ACEC78F1Q44986216-4B1277FF-BFA0-47BB-A0E8-1742FA145241Q45754526-EBBD8FF1-2BFB-47A3-8B07-51C0556DE57AQ46427553-3FDDE614-1D4D-4465-AD6C-B9E64D506E4AQ46591692-5FA1C1C1-6A44-44D6-9B8A-E3DB24705094Q47649268-7D94F1C3-782C-40C0-B9D9-DEDD0744B165Q48966112-B34172A1-41E0-4BE8-93E8-0246FE847B83
P2860
Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Randomized, double-blind, plac ...... ry and cerebrovascular disease
@ast
Randomized, double-blind, plac ...... ry and cerebrovascular disease
@en
Randomized, double-blind, plac ...... ry and cerebrovascular disease
@nl
type
label
Randomized, double-blind, plac ...... ry and cerebrovascular disease
@ast
Randomized, double-blind, plac ...... ry and cerebrovascular disease
@en
Randomized, double-blind, plac ...... ry and cerebrovascular disease
@nl
prefLabel
Randomized, double-blind, plac ...... ry and cerebrovascular disease
@ast
Randomized, double-blind, plac ...... ry and cerebrovascular disease
@en
Randomized, double-blind, plac ...... ry and cerebrovascular disease
@nl
P2093
P50
P1433
P1476
Randomized, double-blind, plac ...... ry and cerebrovascular disease
@en
P2093
Ashfaq Shuaib
Carmen Graffagnino
Desmond Fitzgerald
Donald Easton
Hans-Christophe Diener
James Ferguson
James T Willerson
Jeffrey Granett
Karen Pieper
Kristina Sigmon
P304
P356
10.1161/01.CIR.0000084501.48570.F6
P407
P577
2003-07-29T00:00:00Z